Fieldview Capital Management LLC Acquires Shares of 2,637 Cencora, Inc. $COR

Fieldview Capital Management LLC acquired a new stake in Cencora, Inc. (NYSE:COR) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 2,637 shares of the company’s stock, valued at approximately $891,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in COR. Oakworth Capital Inc. acquired a new stake in shares of Cencora in the 4th quarter valued at about $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora in the 4th quarter valued at about $27,000. Archer Investment Corp raised its stake in shares of Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares in the last quarter. IAG Wealth Partners LLC acquired a new stake in shares of Cencora in the 3rd quarter valued at about $30,000. Finally, Caitlin John LLC acquired a new stake in shares of Cencora in the 3rd quarter valued at about $31,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Price Performance

NYSE COR opened at $281.56 on Monday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The stock has a market cap of $54.78 billion, a price-to-earnings ratio of 21.59, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. The company has a 50-day moving average price of $289.22 and a two-hundred day moving average price of $327.32.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter last year, the company posted $4.42 EPS. Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts forecast that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its board has approved a stock repurchase program on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on COR. Citigroup cut their target price on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. William Blair began coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. Robert W. Baird cut their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Barclays cut their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Weiss Ratings lowered shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $374.00.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.